Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Kimia Biosciences Yönetim

Yönetim kriter kontrolleri 3/4

Kimia Biosciences' CEO'su Sameer Goel, May2022 tarihinde atandı, in görev süresi 2.42 yıldır. şirketin hisselerinin 74.94% doğrudan sahiptir ve bu hisselerin değeri ₹ 1.77B dir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 2.4 yıl ve 8.5 yıldır.

Anahtar bilgiler

Sameer Goel

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	2.4yrs
CEO sahipliği	74.9%
Yönetim ortalama görev süresi	2.4yrs
Yönetim Kurulu ortalama görev süresi	8.5yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Sameer Goel'un ücretlendirmesi Kimia Biosciences'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	n/a	n/a	-₹12m
Mar 31 2024	n/a	n/a	-₹53m
Dec 31 2023	n/a	n/a	-₹133m
Sep 30 2023	n/a	n/a	-₹148m
Jun 30 2023	n/a	n/a	-₹132m
Mar 31 2023	₹6m	n/a	-₹94m
Dec 31 2022	n/a	n/a	-₹46m
Sep 30 2022	n/a	n/a	-₹25m
Jun 30 2022	n/a	n/a	-₹29m
Mar 31 2022	₹6m	n/a	-₹37m
Dec 31 2021	n/a	n/a	-₹32m
Sep 30 2021	n/a	n/a	-₹14m
Jun 30 2021	n/a	n/a	₹34m
Mar 31 2021	n/a	n/a	₹51m
Dec 31 2020	n/a	n/a	₹52m
Sep 30 2020	n/a	n/a	₹49m
Jun 30 2020	n/a	n/a	₹30m
Mar 31 2020	₹444k	₹444k	₹14m
Dec 31 2019	n/a	n/a	₹21m
Sep 30 2019	n/a	n/a	₹40m
Jun 30 2019	n/a	n/a	₹38m
Mar 31 2019	₹5m	₹5m	₹39m

Tazminat ve Piyasa: Sameer şirketinin toplam tazminatının Indian pazarındaki benzer büyüklükteki şirketlerle karşılaştırıldığında makul olup olmadığını tespit etmek için yeterli veri yok.

Tazminat ve Kazançlar: Sameer 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Sameer Goel (49 yo)

2.4yrs

Görev süresi

₹6,000,000

Tazminat

Mr. Sameer Goel has been Chief Executive Officer of Kimia Biosciences Limited since May 30, 2022. He serves as Managing Director of KIMIA Biosciences Pvt. Ltd.Mr. Goel has been the Chairman, Managing Dire...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Sameer Goel	CEO, Chairman of the Board & MD	2.4yrs	₹6.00m	74.94% ₹ 1.7b
Rakesh Chetani	Chief Financial Officer	1.1yrs	Veri yok	Veri yok
Subrat Satpathy	Chief Operating Officer	3.1yrs	₹6.55m	Veri yok
Mathura Joshi	Assistant General Manager of Finance & Accounts	no data	Veri yok	Veri yok
Lakshay Prakash	Company Secretary & Compliance Officer	2.4yrs	Veri yok	Veri yok
Ruchita Mishra	Manager of Marketing	no data	Veri yok	Veri yok
Asit Bhalerao	Chief Human Resources Officer	2.9yrs	₹7.00m	Veri yok
Mukesh Sharma	Head of Research & Development	no data	₹3.59m	Veri yok
Rita Sarin	Advisor of Strategy & IPR Head of Intellectual Property Rights	no data	Veri yok	Veri yok

2.4yrs

Ortalama Görev Süresi

49yo

Ortalama Yaş

Deneyimli Yönetim: 530313 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 2.4 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Sameer Goel	CEO, Chairman of the Board & MD	8.6yrs	₹6.00m	74.94% ₹ 1.7b
Jagdeep Dhawan	Independent Non-Executive Director	8.6yrs	Veri yok	Veri yok
Richa Gupta	Independent Non-Executive Woman Director	8.5yrs	Veri yok	Veri yok
Vipul Goel	Non-Executive Non Independent Director	5.8yrs	Veri yok	0.000030% ₹ 689.4

8.5yrs

Ortalama Görev Süresi

47.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 530313 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 8.5 yıldır).

Kimia Biosciences Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

Insufficient new directors

Kimia Biosciences Limited Announces Chief Financial Officer Changes

Kimia Biosciences Limited, Annual General Meeting, Sep 30, 2023

Kimia Biosciences Limited Announces Appointment of Ms. Mita Namonath Jha as an Additional Director (Non-Executive and Non-Independent Director )

Insufficient new directors

Kimia Biosciences Limited, Annual General Meeting, Sep 30, 2022

Recent updates

First quarter 2025 earnings released: EPS: ₹0.30 (vs ₹0.57 loss in 1Q 2024)

New minor risk - Share price stability

Full year 2024 earnings released: ₹1.12 loss per share (vs ₹1.98 loss in FY 2023)

Kimia Biosciences Limited to Report Q4, 2024 Results on May 30, 2024

Insufficient new directors

New minor risk - Share price stability

Third quarter 2024 earnings released: ₹0.41 loss per share (vs ₹0.98 loss in 3Q 2023)

Kimia Biosciences Limited to Report Q3, 2024 Results on Feb 14, 2024

Second quarter 2024 earnings released: ₹0.52 loss per share (vs ₹0.18 loss in 2Q 2023)

Kimia Biosciences Limited to Report Q4, 2025 Results on May 30, 2025

Kimia Biosciences Limited Announces Chief Financial Officer Changes

Kimia Biosciences Limited, Annual General Meeting, Sep 30, 2023

Kimia Biosciences Limited Announces Appointment of Ms. Mita Namonath Jha as an Additional Director (Non-Executive and Non-Independent Director )

First quarter 2024 earnings released: ₹0.57 loss per share (vs ₹0.23 profit in 1Q 2023)

Full year 2023 earnings released: ₹1.98 loss per share (vs ₹0.78 loss in FY 2022)

Insufficient new directors

Kimia Biosciences Limited to Report First Half, 2023 Results on Nov 14, 2022

Kimia Biosciences Limited to Report Q4, 2023 Results on Apr 12, 2023

Kimia Biosciences Limited, Annual General Meeting, Sep 30, 2022

Kimia Biosciences Limited, Annual General Meeting, Sep 30, 2022

First quarter 2023 earnings released: EPS: ₹0.23 (vs ₹0.07 in 1Q 2022)

Full year 2022 earnings released: ₹0.78 loss per share (vs ₹1.08 profit in FY 2021)

Kimia Biosciences Limited Appoints Sameer Goel as Chief Executive Officer

Kimia Biosciences Limited Announces Resignation of Suneel Kapoor as Chief Executive Officer

Kimia Biosciences Limited Announces Granted Permission to Manufacture and Marketing of Bemopedoic Acid Bulk Drug Under New Drug and Clincial Trials

Kimia Biosciences Limited Announces Appointment of Lakshay Prakash as Company Secretary

Insufficient new directors

Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Kimia Biosciences Limited to Report Q3, 2022 Results on Feb 14, 2022

Insufficient new directors

Company Secretary & Compliance Officer Abhishek Pandey has left the company

First quarter 2022 earnings released: EPS ₹0.07 (vs ₹0.43 in 1Q 2021)

Full year 2021 earnings released: EPS ₹1.08 (vs ₹0.33 in FY 2020)

Investor sentiment improved over the past week

Kimia Biosciences Limited Bags Permission to Manufacture Bilastine API New Active Pharmaceutical Ingredient for Sale or for Distribution

Kimia Biosciences Limited Receives Permission to Manufacture New Active Pharmaceutical Ingredient for Sale or for Distribution

New 90-day low: ₹40.75

Third quarter 2021 earnings released: EPS ₹0.09 (vs ₹0.03 in 3Q 2020)

Kimia Biosciences Limited to Report Q3, 2021 Results on Feb 11, 2021

Investor sentiment improved over the past week

New 90-day high: ₹50.80

New 90-day high: ₹44.95

Market bids up stock over the past week

Market bids up stock over the past week

Kimia Biosciences Limited to Report Q2, 2021 Results on Nov 05, 2020

Kimia Biosciences Limited Approves Appointment of Vipul Goel as Non Executive, Non Independent Director

First quarter earnings released

New 90-day high - ₹33.80

Kimia Biosciences Limited to Report Q1, 2021 Results on Aug 18, 2020

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş